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a  b  s  t  r  a  c  t
Very  late  antigen-4  (VLA-4),  which  is  concerned  with  cell–cell  adhesion,  plays  important  roles  in  devel-
opment  of the heart,  and  some  VLA-4  antagonists  cause  cardiac  anomalies.  In this  study,  we evaluated  the
teratogenic  potential  of  VLA-4  antagonist  derivatives  as screening,  and investigated  the conditions  that
induce cardiac  anomalies.  Seventeen  compounds  were  orally  administered  to pregnant  rats  throughout
the  organogenesis  period,  and  fetal  examinations  were  performed.  In  addition,  drug  concentrations  ineywords:
evelopmental toxicity
entricular septal defect
LA-4
ats
the embryos  were  assayed.  As  a result,  the  incidence  of  ventricular  septal  defect  (VSD) ranged  from  0  to
100%  depending  on  the  compound.  Plasma  drug  concentrations  in the  dams  were  related  to  increased
incidence  of  VSD;  however,  these  incidences  were  not  increased  when  the  concentration  of the  com-
pound  in  the embryos  at 24  h after dosing  was  low.  It is  considered  that  continuous  pharmacological
activity  in the  embryo  for more  than  24 h might  disrupt  closure  of the  ventricular  septum.
©  2014  Published  by  Elsevier  Inc.  This  is  an open  access  article  under  the  CC BY  license. Introduction
Very late antigen-4 (VLA-4) is an integrin consisting of 4 and
1 subunits, and its structure is a heterodimeric transmembrane
lycoprotein. VLA-4, a ﬁbronectin receptor located on endothe-
ial cells, binds to vascular cell adhesion molecule-1 (VCAM-1),
nd this binding causes migration of lymphocytes, monocytes and
osinophils [1].
VLA-4 antagonists are being developed as drugs for asthma,
ecause antagonistic action to VLA-4’s high afﬁnity state (activated
tate concerned in inﬂammatory cell inﬁltration) inhibits adhesion
nd inﬁltration of eosinophilic leukocytes and T-cells to endothe-
ial cells in the blood vessels, and suppress airway inﬂammation
2]. Also, VLA-4 antagonists, including monoclonal antibodies for
4 subunits, are reported to have efﬁcacy in the treatment of mul-
iple sclerosis [3], spinal cord injury [4], and epilepsy [5]. It is also
onsidered that VLA-4’s low afﬁnity state (non-activated state con-
erned in development) plays important roles in hematopoiesis [6],
ifferentiation of skeletal muscle [7], and heart development [8].
Homozygous VLA-4 subunit 4-null mutation leads to lethality
f embryos in mice. In half of such mice, it was observed that the
∗ Corresponding author. Tel.: +81 3 3680 0151; fax: +81 3 5696 8357.
E-mail address: sakurai.ken.t6@daiichisankyo.co.jp (K. Sakurai).
ttp://dx.doi.org/10.1016/j.reprotox.2014.08.003
890-6238/© 2014 Published by Elsevier Inc. This is an open access article under the CC B(http://creativecommons.org/licenses/by/3.0/).
allantois failed to fuse with the chorion during placentation. In the
other half, coronary vessel defects and cardiac hemorrhage were
observed [9]. Similar phenomena were also observed in VCAM-1
deﬁcient mice [10].
Therefore, the potential hazard of VLA-4 antagonists on
embryo/fetal development has been recognized. Consequently,
defects in chorio-allantoic fusion induced by continuous exposure
to small molecule VLA-4 antagonists were shown by an in vitro rat
whole embryo culture system. It was  suggested that the selectivity
of the antagonists for the afﬁnity state of VLA-4 might be related
to the potential hazard to embryo/fetal development. That is, the
selectivity of the antagonist for the high afﬁnity state or low afﬁnity
state might be related to such potential hazard [11]. Spence et al.
suggested that the preferential antagonism for low-afﬁnity VLA-4
induced higher risk in embryo-fetal development [11]. Therefore,
antagonists selective for the high afﬁnity state of VLA-4 are selected
for drug development [12].
In addition, the teratogenic potential of VLA-4 antagonists was
shown in vivo with subcutaneous administration. There were dif-
ferences in the potential among the VLA-4 antagonists, and species
differences were also observed among mice, rats and rabbits [13].
It was  reported that the critical period for heart defects for VLA-4
antagonists in rats is Days 10–11 of gestation, and the teratogenic
potency might be related to pharmacological activity, clearance,
and protein binding [14].
Y license (http://creativecommons.org/licenses/by/3.0/).
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In the present study, we evaluated the teratogenic potential of
7 orally active compounds possessing VLA-4 antagonistic action.
etuses from dams treated orally with the compounds during the
ritical period (Days 10–11 of gestation) were examined. Further,
he effects of treatment during the critical period and throughout
rganogenesis period were compared for 3 compounds. The
elationships between the incidence of cardiac anomaly and
actors such as chemical structure type, antagonism of low afﬁnity
LA-4, maximum drug concentration in plasma (Cmax), and drug
oncentration in the embryo at 24 h after administration, were
nvestigated to ﬁnd the conditions that induce the formation of the
eart anomalies. The interspecies differences in sensitivity to devel-
pmental toxicity were also examined in mice, rats and rabbits.
. Materials and methods
.1. Test articles and administration
Seventeen VLA-4 antagonist compounds (A, B1–3, and Z1–13)
ere synthesized by Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan;
urrently Daiichi Sankyo Pharmaceutical Co., Ltd.). They were sus-
ended in 0.5% methylcellulose solution (0.5% MC) and orally
dministered to the animals based on the body weight on Day 6
r 7 of gestation. In addition, IVL984, which is a VLA-4 antagonist
nd induced cardiac anomalies in rats, rabbits, and mice in a previ-
us report [13], was used as a positive control. IVL984 was  prepared
n 0.15% NaOH and 2.26% glycine for subcutaneous administration.
hemical structures of the 17 compounds and IVL984 are shown
n Fig. 1. Compound A is an amide derivative, compounds B1–B3
re benzoxazole derivatives, and compounds Z1–Z13 are zwitteri-
nic amide derivatives. The positive control compound, IVL984, is
 diphenylurea derivative.
.2. Animals
Nine-week old pregnant female Crj:CD(SD) rats, 9- to 11-week
D-1(ICR) mice, and 5-week old male Crj:CD(SD) rats for toxicoki-
etic (TK) analyses were purchased from Charles River Japan Inc.
Yokohama, Japan). Female Hra:(NZW)SPF rabbits at age 6 months
nd Kbl:NZW rabbits at age 4 months were purchased from Cov-
nce Research Products, Inc. (Denver, PA, USA) and Kitayama Labes
o., Ltd. (Nagano, Japan), respectively. Day 0 of gestation was desig-
ated as the day on which a vaginal plug was found in rats and mice,
nd the day of artiﬁcial insemination in rabbits. The animals were
sed for the present investigation after quarantine and acclima-
ion to the laboratory environment for 3–9 days. All animals were
ndividually housed in metal cages with wire-mesh ﬂoors in an air-
onditioned room with a 12/12-h light/dark cycle, temperature of
3 ± 2 ◦C, relative humidity of 55 ± 20%, and 15 air changes per hour.
aboratory diet (MB-1 for rats and mice, Funabashi Farms, Fun-
bashi, Japan; and RC-4 for rabbits, Oriental Yeast) and chlorinated
ap water were given ad libitum.
All experimental procedures were performed in accordance
ith the “Law concerning the Protection and Control of Animals”
Law No. 105, October 1, 1973, partially revised on December 22,
999 and on June 22, 2005), “Standards Relating to the Care and
anagement, etc. of Experimental Animals” (Notiﬁcation No. 6 of
he Prime Minister’s Ofﬁce, Japan, March 27, 1980, partially revised
n May  28, 2002), and in-house guidelines provided by the Institu-
ional Animal Care and Use Committee of Daiichi Pharmaceutical
o., Ltd..3. Study design in rats
To compare the teratogenicity for cardiovascular system of
arious VLA-4 antagonists in rats, seventeen compounds wereicology 49 (2014) 162–170 163
orally administered to female rats (n = 1–3) on Days 10 and 11 of
gestation at 1000 mg/kg/day as screening studies. IVL984 was sub-
cutaneously administered at 40 mg/kg/day on Days 10 and 11 of
gestation. Animals given 0.5% MC  served as negative controls (n = 2).
The dosing period was  determined based on the results of the ref-
erence study in which marked visceral anomalies in the fetus were
observed [14]. The dams were anesthetized with ether inhalation
and euthanized by exsanguination via the abdominal aorta on Day
21 of gestation, and then fetuses were removed. The number of
fetuses, viability, sex ratio, body weight, and external and visceral
anomalies [15] were examined.
Additionally, as representative compounds of each scaffold, 3
compounds (A, B3 and Z9) were administered orally and IVL984 was
administered subcutaneously to rats (n = 7–20) throughout organo-
genesis period (from Day 6 or 7–17 of gestation) to investigate the
effects on external, visceral, and skeletal developments. Thus, in
addition to the examinations mentioned above, skeletal anomalies
were also examined [16]. Animals given 5 mL/kg of 0.5% MC  served
as negative controls (n = 20).
2.4. Antagonism against low-afﬁnity (non-activated state) VLA-4
To investigate the relationship between teratogenicity and
selectivity to high- (activated state) or low-afﬁnity (non-activated
state) VLA-4, the inhibitory effects of 14 compounds (A, B3, Z2–13)
and IVL984 on binding of high- or low-afﬁnity VLA-4 to VCAM-1
were investigated in the presence or absence of Mn2+, respectively.
Chinese hamster ovary (CHO) cells stably expressing human VLA-
4 that were established by Pharmacopeia, Inc. (Cranbury, NJ, USA)
were maintained in an F-12 nutrient mixture (Ham’s F-12: Sigma,
St. Louis, MO,  USA) supplemented with 10% fetal calf serum (REHA-
TUIN Fetal Bovine Serum, Serologicals Corporation, Norcross, GA,
USA) and 1 mg/ml  G418 (Geneticin, Invitrogen Corporation, Carls-
bad, CA, USA). Prior to assay, 3 × 104 cells were distributed into each
well of 96-well culture plates and incubated at 37 ◦C with 5% CO2 for
2 days. Then the cells were washed with chilled wash buffer twice.
Assay buffer containing VLA-4 antagonists at various concentra-
tions and 2 nM europium-labeled human VCAM-1-Ig were added
to the wells in duplicate. The plates were incubated for 60 min
at room temperature, and the wells were washed 4 times with
chilled wash buffer. DELFIA enhancement solution was added to
each well and the plates were shaken on a plate shaker for several
minutes. The ﬂuorescence was  measured using a time-resolved ﬂu-
orometer (Dissociation enhanced lanthanide ﬂuoroimmunoassay
[DELFIA] Research Fluorometer; model 1234-001; PerkinElmer).
The concentration of compound required for 50% inhibition of bind-
ing between VLA-4 and VCAM-1 in the assay was determined.
2.5. Toxicokinetics
To investigate the relationship between blood levels of the drug
and teratogenicity, fourteen compounds (A, B1–3, Z1–2, 4, 6–12)
were orally administered to 5 week-old male rats (n = 4–5) at
500 mg/kg. A 0.4 mL  blood sample was obtained via the jugular vein
at 0.5, 2 and 24 h after dosing. In addition, to investigate the rela-
tionship between teratogenicity and persistence of drug exposure
in dams and embryos, representative six compounds (A, B2, B3, Z2,
Z3 or Z8) from each scaffold were orally administered to pregnant
female rats (n = 2–3) on Day 11 of gestation at 1000 mg/kg. A 2 mL
blood sample was withdrawn via the jugular vein at 2 and 24 h after
dosing, and then the pregnant females were euthanized. Embryos
were removed and those from each litter were pooled.Plasma was  separated by centrifugation (4 ◦C, 1200 × g, 15 min).
Plasma and embryo samples were stored in a freezer at −80 ◦C
prior to analysis. Drug concentrations in plasma and embryo
samples were measured at the Sekisui Medical Co., Ltd. by a
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Fig. 1. Chemical structures of VLA-4 antagonist derivatives. Compound A is an amide derivative, compounds B1–B3 are benzoxazole derivatives, compounds Z1–Z13 are
zwitterionic amide derivatives, and the positive control compound, IVL984, is a diphenylurea derivative.
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iquid chromatography/mass spectrometry/mass spectrometry
LC/MS/MS) method.
.6. Species comparison studies
To investigate the differences in the incidence and type of
nomalies among mice, rats, and rabbits, two compounds, A and
3, were also investigated in CD-1(ICR) mice and Hra:(NZW)SPF
r Kbl:NZW rabbits. These compounds were orally administered
o female mice (n = 6–7) from Day 7–12 of gestation at a dose of
000 mg/kg/day. The dams were euthanized on Day 18 of ges-
ation, and then fetuses were removed. Compound A was orally
dministered to female Hra:(NZW)SPF rabbits (n = 19–21) from Day
–20 of gestation at a dose of 1000 mg/kg/day. Compound B3 was
rally administered to female Kbl:NZW rabbits (n = 1–2) from Day
–11 of gestation at 600 or 1000 mg/kg/day. The dams were euth-
nized on Day 29 of gestation, and then fetuses were removed, and
he number of fetuses, viability, sex ratio, body weight, and exter-
al, visceral, and skeletal anomalies were examined. Animals given
 mL/kg of 0.5% MC  served as a negative control..7. Statistical analyses
Statistical analyses were conducted in the species comparison
tudies, except for the study of compound B3 in rabbits. For the fetal
ig. 2. Representative macroscopic ﬁndings in the internal view of the heart of
etuses from rat dams given a VLA-4 antagonist from Days 10 to 11 of gestation:
A)  normal ventricle; (B) VSD. Arrow shows the VSD. LV: left ventricle, Ao: aorta.icology 49 (2014) 162–170 165
mortality and incidence of visceral anomalies, the litter was used
as the sample unit and the mean percentage for each group was
calculated. Analyses were done using Wilcoxon’s rank sum test. A
P value less than 5% (two-tailed) was considered to show statistical
signiﬁcance. EXSAS ver.6.10 (CAC Corporation, Tokyo, Japan) was
used for these statistical analyses.
3. Results
3.1. Incidence of VSD and SLA in rats
Ventricular septal defect (VSD, Fig. 2) and small left atrial cham-
ber (SLA, Fig. 3) were observed after dosing with 1000 mg/kg/day of
each VLA-4 antagonist compound to rats on Days 10 and 11 of gesta-
tion. For the group given the positive control, IVL984, the incidences
of VSD and SLA were 38.4 and 100%, respectively, and those in the
negative control were 3.6 and 0%, respectively (Table 1). As shown
in Fig. 4, the incidence of VSD was less than 5% in 5 compounds
(compounds A, Z2, Z7, Z9, and Z10), 5% or more and less than 10%
in 3 compounds (compounds Z5, Z11, and Z12), and 10% or more
in the remaining 9 compounds. SLA was  noted in 7 compounds
(compounds B1–B3, Z1, Z4, Z8, and Z13) and with an incidence of
39% or more, but was not noted in the other 10 compounds. VSD
was observed with incidence of 10% or more in the 8 compounds
including IVL984 in which SLA was  detected (Fig. 4).
Fig. 3. Representative macroscopic ﬁndings of the heart of fetuses from rat dams
treated orally with a VLA-4 antagonist derivative from Days 10 to 11 of gestation:
(A)  normal left atrial chamber; (B) SLA. Arrow shows normal left atrial chamber (A)
or  SLA (B). RA: right atrium, LA: left atrium, RV: right ventricle, LV:  left ventricle.
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Table 1
Mortality and visceral anomalies of fetuses from rat dams given VLA-4 antagonists orally at 1000 mg/kg/day.
Code no. Controla A B3 Z9 IVL984b
Dosing period (gestation day) 10–11 6–17 10–11 6–17 10–11 7–17 10–11 6–17 10–11 7–17
No. of dams 2 20 3 20 3 7 3 10 2 8
Fetal  mortality (%)c 8.4 4.0 5.1 4.9 9.0 24.9 0.0 4.2 21.9 57.5
SD  – 5.5 4.5 9.6 10.1 25.0 – 4.8 – 26.1
No.  of fetuses observed 23 131 39 130 41 35 32 67 25 29
Ventricular septal defect (%)c 3.6 2.1 2.2 0.0 18.3 48.0 2.4 3.1 38.4 61.3
SD  – 5.2 3.9 – 13.7 32.9 4.1 6.6 – 31.2
Small  left atrial chamber (%)c 0.0 0.0 0.0 0.0 65.1 51.7 0.0 0.0 100.0 100.0
SD  – – – – 50.1 45.9 – – – –
Anophthalmia (%)c 0.0 0.0 0.0 0.0 2.1 26.8 0.0 0.0 0.0 0.0
SD  – – – – 3.6 36.3 – – – –
Small  thymus (%)c 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 20.0 25.4
SD  – – – – – 18.9 – – – 32.9
SD, standard deviation.
c
e
c
1
0
i
d
F
aa 0.5% MC was  administered orally.
b IVL984 was administered subcutaneously at 40 mg/kg/day.
c Values represent the group average of litter percentages.
The incidence in visceral anomalies caused by dosing of 3
ompounds during the critical period or throughout organogen-
sis period is shown in Table 1. For the group given the positive
ontrol, IVL984, the incidences of VSD and SLA were 61.3 and
00%, respectively, and those in the negative control were 2.1 and
%, respectively, by dosing throughout organogenesis period. No
ncreased incidence of VSD or SLA was observed in critical-period
osing with compound A or Z9, and no changes were noted even
ig. 4. Incidence of VSD and SLA in fetuses from rat dams (n = 1–3) treated orally with v
dministered subcutaneously at 40 mg/kg/day. The ﬁgures above each bar represent the awith dosing throughout the organogenesis period. Increased inci-
dences of VSD and SLA were observed in critical-period dosing
of compound B3; VSD incidence tended to increase further after
throughout organogenesis-period dosing, but SLA incidence was
similar to that after critical-period dosing. The incidence of anoph-
thalmia observed in groups treated with compound B3 increased
from 2.1 to 26.8% when the dosing period was extended. On the
other hand, the incidences of small thymus were similar between
arious VLA-4 antagonists at 1000 mg/kg or 0.5% methylcellulose (MC). IVL984 was
ctual values.
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Fig. 6. Relationship between plasma drug concentration (Cmax) in male rats (n = 4–5)
given 500 mg/kg of various VLA-4 antagonists and incidence of VSD or SLA in fetusesig. 5. Relationship between antagonism of low-afﬁnity VLA-4 and incidence of
SD  or SLA in fetuses from rat dams (n = 1–3) treated orally with various VLA-4
ntagonists at 1000 mg/kg. Grading of incidence: +, ≥10%; ±, ≥5% and <10%; −, <5%.
he two dosing periods, and actually, small thymus was  observed
n only one litter even after organogenesis-period dosing of com-
ound B3. In the positive control group, increased incidence of
mall thymus was also observed.
.2. Antagonism against low-afﬁnity VLA-4 and incidence of VSD
nd SLA
Antagonism of low-afﬁnity VLA-4 and incidence of VSD and SLA
re shown in Fig. 5. The IC50 value of IVL984, the strongest inhibitor,
as 1 nM,  and that of compound A, the weakest inhibitor, was
960 nM,  giving a ratio of approximately 10,000. No relationship
etween antagonism of low-afﬁnity VLA-4 and the incidence of VSD
r SLA was observed..3. Drug concentrations and incidence of VSD and SLA
Fourteen VLA-4 antagonists were orally administered to male
ats at 500 mg/kg. Cmax and the corresponding incidence of VSD andfrom rat dams (n = 1–3) given 1000 mg/kg of VLA-4 antagonists. Grading of inci-
dence: +, ≥10%; ±, ≥5% and <10%; −, <5%.
SLA for each compound were shown in Fig. 6. VSD was observed in
7 compounds with the incidence of 10% or more, and SLA was also
seen in 6 of these same compounds. Plasma drug concentrations
of these compounds that induced VSD were higher than those of
the other compounds except for compound A. Cmax of compound
A was higher than that of compound Z4, even though neither VSD
nor SLA was noted in the group treated with compound A, and the
incidences in the group treated with compound Z4 were 25.1% for
VSD and 38.9% for SLA.
The drug concentrations dams’ plasma and embryos at 2 and
24 h after dosing for 6 compounds and the incidence of VSD and
SLA are shown in Fig. 7. At 2 h after dosing, the drug concentrations
of compounds A, B2, B3, and Z8 in plasma and embryo were higher
than those of compounds Z2 and Z3. At 24 h after dosing, drug
concentrations in both plasma and embryo of compounds B2, B3,
and Z8 remained at high levels, however that of compound A was
almost zero.
3.4. Studies in mice and rabbits
Fetal mortality and incidence of visceral anomalies after treat-
ment with compounds A and B3 in mice, rats, and rabbits are shown
in Table 2. In animals treated with compound A, no differences were
observed between control and treated groups in any species. In
studies with compound B3, although increased incidences of VSD,
SLA, and anophthalmia were noted in rats, no visceral anomalies
were seen in mice. All fetuses died at 1000 mg/kg/day in rabbits.
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Vig. 7. Relationship between drug concentrations in plasma of dams and in whol
arious VLA-4 antagonists.
etal mortality in rabbits was higher than that in rats (24.9%) at the
ame dose level, although only 2 litters were evaluated in rabbits.
. Discussion
In the present study, 17 VLA-4 antagonist derivatives were given
rally to pregnant rats on Days 10 and 11 of gestation, and the car-
iac anomalies VSD and SLA were observed in their fetuses with
ncidence ranging from 0 to 100%. Although the teratogenicity of
LA-4 antagonists given by the subcutaneous route was previously
eported, VSD and SLA were observed after dosing by the oral route
n the present study. Under normal conditions, VSD is sometimes
bserved as a spontaneous anomaly, but SLA is not common [17].
n terms of chemical structure, the incidence of anomalies was
ow with the amide type and high with the benzoxazole type, but
–100% with the zwitterionic amide type, suggesting the incidence
s related to not only the type of scaffold structure but also to the
able 2
ortality and visceral anomalies of mouse, rat or rabbit fetuses from dams given VLA-4 a
Code no. A 
Species (dosing period) Mice (GD7-12) Rats (GD6-17) Rabbits (GD6
Dose (mg/kg/day) Control 1000 Control 1000 Control 
No. of dams 6 6 20 20 19 2
Fetal  mortality (%)a 6.9 9.2 4.0 4.9 1.7 
SD  6.0 16.3 5.5 9.6 5.3 1
No.  of fetuses observed 78 81 131 130 158 17
VSD  (%)a 0.0 0.0 2.1 0.0 0.0 
SD  – – 5.2 – – 
SLA  (%)a 0.0 0.0 0.0 0.0 0.0 
SD  – – – – – 
Anophthalmia (%)a 0.0 0.0 0.0 0.0 0.0 
SD  – – – – – 
.5% MC was  administered orally (10 mL/kg) for control.
SD, ventricular septal defect; SLA, small left atrial chamber; GD, gestation day; SD, stand
* P < 0.05 signiﬁcant difference from control.
a Values represent the group average of litter percentages.ryos and incidence of VSD and SLA in fetuses from rat dams given 1000 mg/kg of
side chain structure and salt form. Actually, the incidence of VSD
with compound Z8 was  higher than that with compound Z2, even
though these 2 compounds have the same scaffold. The difference
might be related to whether the blood levels are maintained, and
it depends on the side chain structure and salt form.
Research into the malformations induced by VLA-4 antagonists
has been especially focused on the structural anomalies in the pla-
centa or heart so far. However, anophthalmia was observed with B3
of the present study. It is known that VLA-4 and VCAM-1 are related
to not only chorio-allantoic fusion or formation of the ventricular
septum but also to differentiation in other organs. Actually, VLA-4 is
important for survival and development of retinal neurons includ-
ing retinal ganglion cells [18]. However, considering the fact that
most of the compounds did not induce anophthalmia in this study,
occurrence of anophthalmia might be unrelated to the treatment
of VLA-4 antagonist.
For compounds A and Z9, the incidences of cardiac anoma-
lies did not increase in the critical-period dosing study nor in the
ntagonists orally.
B3
-18) Mice (GD7-12) Rats (GD7-17) Rabbits (GD8-11)
1000 Control 1000 Control 1000 Control 600 1000
1 7 6 10 7 2 1 2
5.7 10.2 18.0 4.7 24.9 0.0 55.6 100.0
0.3 16.5 14.4 5.4 25.0 – – –
4 84 75 59 35 23 4 0
0.0 0.0 0.0 6.0 48.0* 0.0 50.0 –
– – – 14.0 32.9 – – –
0.0 0.0 0.0 0.0 51.7* 0.0 50.0 –
– – – – 45.9 – – –
0.0 0.0 0.0 0.0 26.8* 0.0 0.0 –
– – – – 36.3 – – –
ard deviation.
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[
[K. Sakurai et al. / Reproducti
rganogenesis-period dosing study. In the case of compound B3
nd IVL984, the occurrence of SLA and small thymus was  similar
hether the test compound was given during Days 10–11 of gesta-
ion or during the entire organogenesis period; on the other hand,
he incidences of VSD and anophthalmia were higher when the
ompound was given throughout the organogenesis period than
hen it was given only on Days 10–11 of gestation. Though the
evels in dams’ plasma and embryos after multiple dosing were
ot determined, these results suggest that the critical periods for
SD and anophthalmia by these VLA-4 antagonists encompass Days
0–11 of gestation and beyond. Generally, it is thought that the
ritical periods for VSD and anophthalmia in rats are Days 7–15
nd Days 8–9 of gestation, respectively [19,20]. This is consistent
ith the results in this study, which showed that the incidence of
SD in the organogenesis dosing study was higher than that in the
ritical-period dosing study.
In the present study, species differences in teratogenicity were
lso investigated among mice, rats, and rabbits given compounds
 and B3. There were no increases in either fetal mortality or fetal
nomalies in any species given 1000 mg/kg of compound A. Com-
ound B3 at the dose of 1000 mg/kg showed no teratogenicity in
ice, but increased incidence of VSD, SLA, and anophthalmia were
bserved in rats. Severe fetal mortality was noted in rabbits only.
dditionally in rabbits, treatment with 600 mg/kg of compound B3
esulted in death in more than half of the fetuses and some of the
urviving fetuses showed cardiac anomalies. These results suggest
 possibility of species differences for VLA-4 antagonists, although
he number of rabbits that could be evaluated was  only one dam
t 600 mg/kg. Crofts et al. reported a similar tendency as shown in
his study, that is, higher sensitivity in rabbits than in rats [13].
Spence et al. reported that anomalies in the placenta were
nduced not by antagonists that are selective for high-afﬁnity VLA-
 but by high-afﬁnity VLA-4 non-selective antagonists in an in vitro
odel, indicating a relationship between activation states and
afety of the embryo [11]. However, no relationship between the
ntagonism of low-afﬁnity VLA-4 and the incidence of VSD and SLA
as observed in the present study. Therefore, selectivity for activa-
ion states of VLA-4 might not be related to occurrence of VSD and
LA.
Maximum drug concentrations (Cmax) in plasma from males
ere positively associated with the increases in the incidence of
SD and SLA in most compounds; however, this relationship could
ot be found in some compounds. Drug concentration of compound
 was higher than that of compound Z4, but the incidence of VSD
nd SLA after treatment with compound A was lower than that after
reatment with compound Z4.
The incidence of cardiac anomalies corresponded more to the
rug concentration in the embryo than in the plasma of dam, and
lso more to the drug concentration at 24 h after dosing than at 2 h
fter dosing. The incidence of cardiac anomalies was not increased
n the groups in which almost no test drug was  present in the
mbryo at 24 h after dosing except for compound Z3.
Therefore, the compounds for which concentrations in the
mbryos are maintained at high level still at 24 h after dosing on
ay 11 of gestation are considered to continuously inhibit cell
dhesion over 24 h and evoke the cardiac anomaly. On the other
and, some compounds did not maintain consistent inhibition over
4 h since they were not detected in embryos at 24 h after dosing,
uggesting that cell adhesion could occur during low exposure in
mbryos. Consequently, the important point for the occurrence of
ardiac anomaly by VLA-4 antagonists in rats is considered to be the
learance which produces low enough trough levels to allow cell
dhesion, rather than the peak level of the drug in dams or embryos.
Regarding compound Z3, in spite of low concentration in dams
nd embryos, the incidence of VSD was more than 10%. For the
ther compounds, in vivo results were as expected based on in vitro
[
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results, but for compound Z3, the incidence of malformations was
much higher than expected based on in vitro results, suggesting
the existence of a metabolite of compound Z3 with VLA-4 antago-
nistic potential. It is thought that the concentration of unchanged
drug was low but the concentration of active metabolite was  high
enough to induce the cardiac anomaly.
In conclusion, it is considered that continuous interruption of
cell–cell adhesion by VLA-4 antagonists for more than 24 h in the
embryo might induce speciﬁc cardiac anomalies.
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